var data={"title":"Nitroglycerin (glyceryl trinitrate): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitroglycerin (glyceryl trinitrate): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6662?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">see &quot;Nitroglycerin (glyceryl trinitrate): Drug information&quot;</a> and <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitroglycerin (glyceryl trinitrate): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202098\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GoNitro;</li>\n      <li>Minitran;</li>\n      <li>Nitro-Bid;</li>\n      <li>Nitro-Dur;</li>\n      <li>Nitro-Time;</li>\n      <li>Nitrolingual;</li>\n      <li>NitroMist;</li>\n      <li>Nitronal [DSC];</li>\n      <li>Nitrostat;</li>\n      <li>Rectiv</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202099\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Minitran;</li>\n      <li>Mylan-Nitro Sublingual Spray;</li>\n      <li>Nitro-Dur;</li>\n      <li>Nitroglycerin Injection, USP;</li>\n      <li>Nitrol;</li>\n      <li>Nitrostat;</li>\n      <li>Rho-Nitro Pump Spray;</li>\n      <li>Transderm-Nitro;</li>\n      <li>Trinipatch</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054421\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianginal Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nitrate</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasodilator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasodilator, Coronary</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675227\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vasodilation; perioperative, congenital heart defect repair:</b> Limited data available: Continuous IV infusion: Initial: 0.25 to 0.5 mcg/kg/minute; titrate by 0.5 to 1 mcg/kg/minute every 3 to 5 minutes as needed; usual dose: 1 to 3 mcg/kg/minute; usual maximum dose: 5 mcg/kg/minute. In one clinical study of 16 pediatric patients &lt;24 months of age (median: 4.4 months, range: 3 days to 23.7 months), a median dose of 1.8 mcg/kg/minute (range: 0.5 to 4 mcg/kg/minute) was reported following cardiac surgery with bypass (Williams 1994); another trial describes a fixed dose of 1 mcg/kg/minute administered to 15 neonates (mean: 8 days of age) after cardiac surgery in conjunction with dopamine (Laitinen 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation (sympathomimetic vasopressors), treatment (alternative to phentolamine):</b> Very limited data available; dosing regimens highly variable: Topical: 2% ointment: 4 <b>mm</b>/kg applied as a thin ribbon to the affected areas; after 8 hours if no improvement, the dose may be repeated at the site; dosing based on a case series in four premature neonates (GA: 24 to 31 weeks; at time of treatment: weight: 670 to 1,565 g; PNA: 4 to 40 days) (Wong 1992). A case report in a premature neonate (GA: 34 weeks; weight: 1,800 g) describes a higher dose of a 1-inch strip (total dose) applied to the affected sites (ankle and wrist) (Denkler 1989); however, this is greater than the usual initial adult dose (<sup>1</sup>/<sub>2</sub> inch) for angina; hypotension may occur; carefully monitor blood pressure (Reynolds 2014). <b>Note:</b> Minimal data available from clinical trials/case reports; however, use is described in neonatal extravasation treatment protocols (Restieaux 2013; Sawatzky-Dickson 2006; Thigpen 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054413\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">see &quot;Nitroglycerin (glyceryl trinitrate): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Continuous IV infusion dosing units vary by age (mcg/kg/minute or <b>mcg/minute</b>); extra precautions should be taken. Tolerance to the hemodynamic and antianginal effects can develop within 24 to 48 hours of continuous use. Nitrate-free interval (10 to 12 hours/day) is recommended to avoid tolerance development; gradually decrease dose in patients receiving nitroglycerin for prolonged periods to avoid withdrawal reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure; cardiogenic shock:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Continuous IV infusion: Initial: 0.25 to 0.5 mcg/kg/minute; titrate by 1 mcg/kg/minute every 15 to 20 minutes as needed; faster titration may be necessary in some patients; in adolescents, titration every 3 to 5 minutes has been suggested; usual dose range: 1 to 5 mcg/kg/minute; usual maximum dose: 10 mcg/kg/minute (AHA [Chameides 2011]; Artman 1987; Ilbawi 1985; Park 2014); doses up to 20 mcg/kg/minute may be used (Friedman 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Continuous IV infusion: Initial: 5 to 10 <b>mcg/minute</b>; titrate every 3 to 5 minutes as needed to maximum rate of 200 <b>mcg/minute</b> (AHA [Chameides 2011]; Park 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation (sympathomimetic vasopressors), treatment (alternative to phentolamine):</b> Very limited data available; dosing based on experience in neonatal patients; optimal dosing has not been established: Infants, Children, and Adolescents: Topical: 2% ointment: 4 <b>mm</b>/kg applied as a thin ribbon to the affected areas; after 8 hours if no improvement, the dose may be repeated at the affected site (Wong 1992). The maximum reported dose  is application of a 1-inch strip to the affected site in a neonate (Denkler 1989); however, this is greater than the usual initial adult dose (<sup>1</sup>/<sub>2</sub> inch) for angina; hypotension may occur; carefully monitor blood pressure (Reynolds 2014). <b>Note:</b> Minimal data available from clinical trials/case reports; however, use has been described in reviews of extravasation treatment (Reynolds 2014; Treadwell 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anal fissure, chronic:</b> 0.4% ointment: Intra-anal: 1 inch (equals 1.5 mg of nitroglycerin) every 12 hours for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Angina/coronary artery disease: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial: 5 mcg/minute, increase by 5 mcg/minute every 3 to 5 minutes to 20 mcg/minute; if no response at 20 mcg/minute, may increase as needed by 10 to 20 mcg/minute every 3 to 5 minutes (generally accepted maximum dose: 400 mcg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2.5 to 6.5 mg 3 to 4 times daily (maximum dose: 26 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patch, transdermal: Initial: 0.2 to 0.4 mg/hour, titrate to 0.4 to 0.8 mg/hour; tolerance is minimized by using a &quot;patch-on&quot; period of 12 to 14 hours per day and a &quot;patch-off&quot; period of 10 to 12 hours per day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual powder (0.4 mg/packet): 1 to 2 packets under tongue every 5 minutes as needed for maximum of 3 packets in 15 minutes; may also use prophylactically 5 to 10 minutes prior to activities which may provoke an angina attack</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet: 0.3 to 0.6 mg every 5 minutes for maximum of 3 doses in 15 minutes; may also use prophylactically 5 to 10 minutes prior to activities which may provoke an attack</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical: 2% ointment: Apply 0.5 inch upon rising and 0.5 inch 6 hours later; if necessary, the dose may be doubled to 1 inch and subsequently doubled again to 2 inches if response is inadequate. Doses of 0.5 to 2 inches were used in clinical trials. Recommended maximum: 2 doses/day; include a nitrate-free interval ~10 to 12 hours/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Translingual: 0.4 mg/spray: 1 to 2 sprays onto or under tongue approximately every 5 minutes for maximum of 3 sprays in 15 minutes; may also be used prophylactically 5 to 10 minutes before activities that may provoke an angina attack</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202076\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Translingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NitroMist: 400 mcg/spray (4.1 g, 8.5 g) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mcg/spray (4.1 g [DSC], 8.5 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Time: 2.5 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Time: 6.5 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Time: 9 mg [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 6.5 mg, 9 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectiv: 0.4% (30 g) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Bid: 2% (1 g, 30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoNitro: 400 mcg (1 ea, 36 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch 24 Hour, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minitran: 0.1 mg/hr (30 ea); 0.2 mg/hr (30 ea); 0.4 mg/hr (30 ea); 0.6 mg/hr (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitro-Dur: 0.1 mg/hr (30 ea, 100 ea); 0.2 mg/hr (30 ea, 100 ea); 0.3 mg/hr (1 ea, 30 ea, 100 ea); 0.4 mg/hr (30 ea, 100 ea); 0.6 mg/hr (30 ea, 100 ea); 0.8 mg/hr (30 ea, 100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg/hr (1 ea, 30 ea, 4350 ea); 0.2 mg/hr (1 ea, 30 ea, 4350 ea); 0.4 mg/hr (1 ea, 30 ea, 4350 ea); 0.6 mg/hr (1 ea, 30 ea, 4350 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitronal: 1 mg/mL (25 mL [DSC], 50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg (250 mL); 50 mg (250 mL, 500 mL [DSC]); 100 mg (250 mL); 200 mg (500 mL [DSC]); 5 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Translingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitrolingual: 0.4 mg/spray (4.9 g, 12 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/spray (4.9 g, 12 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitrostat: 0.3 mg, 0.4 mg, 0.6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.3 mg, 0.4 mg, 0.6 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202061\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50063776\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Nitronal IV solution has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054425\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-anal ointment: Using a finger covering (eg, plastic wrap, surgical glove, finger cot), place finger beside 1 inch measuring guide on the box and squeeze ointment the length of the measuring line directly onto covered finger. Insert ointment into the anal canal using the covered finger up to first finger joint (do not insert further than the first finger joint) and apply ointment around the side of the anal canal. If intra-anal application is too painful, may apply the ointment to the outside of the anus. Wash hands following application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule (extended release): Administer with a full glass of water on an empty stomach; swallow whole, do not crush or chew</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual powder: Empty the contents of packet under the tongue, close mouth, and breathe normally. Allow powder to dissolve without swallowing. Do not rinse or spit for 5 minutes after dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet: Place under tongue and allow to dissolve, do not swallow, chew, or crush; do not eat or drink while tablet dissolves. Alternately, may be placed in the buccal pouch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Translingual spray: Do not shake container. Pump must be primed prior to first use by spraying 5 times (Nitrolingual) or 10 times (Nitromist); direct priming sprays into the air, away from patient and others; if pump is unused for 6 weeks, a single priming spray (Nitrolingual) or 2 priming sprays (Nitromist) should be completed; if pump is unused for 3 months, reprime with up to 5 sprays (Nitrolingual). To administer dose, spray onto or under tongue with container as close to mouth as possible; close mouth after administration; do not inhale spray; avoid swallowing immediately after spray; do not expectorate or rinse mouth for 5 to 10 minutes after use. Content of the container should be checked periodically; when the container is held upright, the end of the pump should be covered by the fluid in the bottle or the remaining sprays will not deliver the intended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Continuous IV infusion: Administer via infusion pump. Adsorption occurs to soft plastic (eg, PVC); special administration sets intended for nitroglycerin (nonpolyvinyl chloride) must be used</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Place on hair-free area of skin; rotate patch sites; <b>Note:</b> Some products are a membrane-controlled system (eg, Transderm-Nitro); do <b>not</b> cut these patches to deliver partial doses; rate of drug delivery, reservoir contents, and adhesion may be affected; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (Lee 1997 and see specific product labeling)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472968\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 100 <b>mcg</b>/mL, 200 <b>mcg</b>/mL, or 400 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202093\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV solution: Store nitroglycerin premixed with dextrose at 25&deg;C (77&deg;F); brief exposure up to 40&deg;C (104&deg;F) does not adversely affect the product. Protect from light until time of use. Avoid excessive heat; protect from freezing. Nitroglycerin diluted in D5W or NS in glass containers is physically and chemically stable for 48 hours at room temperature and 7 days under refrigeration. In D5W or NS in EXCEL/PAB containers it is physically and chemically stable for 24 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual powder: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 5&deg;C to 40&deg;C (41&deg;F to 104&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in original glass container.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Translingual spray: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not forcefully open or burn container after use. Do not spray toward flames.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054424\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release capsule, topical ointment (Nitro-Bid), transdermal patch (NitroDur, Minitran): Prevention of angina pectoris (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV solution: Treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and beta-blockers; acute decompensated heart failure (especially when associated with acute myocardial infarction); perioperative hypertension (especially during cardiovascular surgery); induction of intraoperative hypotension (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual powder (GoNitro), sublingual tablets (NitroStat), sublingual spray (Nitrolingual, NitroMist): Treatment or prevention of angina pectoris (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal ointment (Rectiv): Treatment of moderate to severe pain associated with chronic anal fissure (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202157\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitroglycerin may be confused with nitrofurantoin, nitroprusside</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitro-Bid may be confused with Macrobid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitroderm may be confused with NicoDerm</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrol may be confused with Nizoral</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrostat may be confused with Nilstat, nystatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Vasodilators are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older with a history of syncope due to its potential to exacerbate episodes of syncope (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrocor [Italy, Russia, and Venezuela] may be confused with Natrecor brand name for nesiritide [US, Canada, and multiple international markets]; Nutracort brand name for hydrocortisone in the [US and multiple international markets]; Nitro-Dur [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4040395\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, exacerbation of angina pectoris, flushing, hypotension, orthostatic hypotension, peripheral edema (lingual spray), syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache (more common with patch, ointment), paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (lingual spray), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness (all sublingual forms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pharyngitis (lingual spray), rhinitis (lingual spray)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug tolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, application site irritation (patch), circulatory shock, contact dermatitis (ointment, patch), drowsiness, exfoliative dermatitis, fixed drug eruption (ointment, patch), hypersensitivity reaction, hypoxemia (transient), methemoglobinemia, nausea, pallor, palpitations, rebound hypertension, restlessness, skin rash, tachycardia, vertigo, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nitroglycerin, other nitrates or nitrites, or any component of the formulation (includes adhesives for transdermal product); concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (avanafil, sildenafil, tadalafil, or vardenafil); concurrent use with soluble guanylate cyclase (sGC) stimulators (eg, riociguat).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for IV product: Hypersensitivity to corn or corn products (solutions containing dextrose); constrictive pericarditis; increased intracranial pressure; pericardial tamponade; restrictive cardiomyopathy; uncorrected hypovolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for sublingual product and rectal ointment: Acute circulatory failure or shock (sublingual tablets and powder); early myocardial infarction (sublingual tablet only; see <b>Note</b>); increased intracranial pressure; severe anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for translingual product: Increased intracranial pressure; severe anemia; acute circulatory failure or shock (Nitrolingual only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications for translingual product (not in US labeling): Closed angle glaucoma; myocardial infarction; heart failure (aortic or mitral stenosis, constrictive pericarditis or hypertrophic obstructive cardiomyopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications for transdermal patch (not in US labeling): Acute circulatory failure associated with marked hypotension (shock and states of collapse); orthostatic hypotension; myocardial insufficiency due to obstruction (eg, presence of aortic or mitral stenosis or of constrictive pericarditis); increased intracranial pressure; increased intraocular pressure; severe anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> According to the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines of the management of ST-elevation myocardial infarction (STEMI) and the ACC/AHA guidelines for the management of patients with non-ST-elevation acute coronary syndromes (NSTE-ACS), avoid nitrates in the following conditions: Hypotension (SBP &lt;90 mm Hg or &ge;30 mm Hg below baseline), marked bradycardia or tachycardia, and right ventricular infarction (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]). Sublingual nitroglycerin may be used as initial treatment of ongoing chest pain in patients who may have STEMI or NSTE-ACS (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202065\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Headache: Dose-related headaches may occur, especially during initial dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/bradycardia: Severe hypotension and shock may occur (even with small doses); paradoxical bradycardia and increased angina pectoris may accompany hypotension. Orthostatic hypotension may also occur; ethanol may accentuate this. Use with caution in volume depletion, preexisting hypotension, constrictive pericarditis, aortic or mitral stenosis, and extreme caution with inferior wall MI and suspected right ventricular involvement. According to the ACCF/AHA, avoid use in patients with severe hypotension (SBP &lt;90 mm Hg or &ge;30 mm Hg below baseline), marked bradycardia or tachycardia, and right ventricular MI (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Nitroglycerin may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008). Some products are contraindicated in patients with increased intracranial pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (ACCF/AHA [Gersh, 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intra-anal ointment: Use caution when treating rectal anal fissures with nitroglycerin in patients with suspected or known significant cardiovascular disorders (eg, cardiomyopathies, heart failure, acute MI); intra-anal nitroglycerin administration may decrease systolic blood pressure and decrease arterial vascular resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-acting agents: Avoid use of long-acting agents in acute MI or acute HF; cannot easily reverse effects if adverse events develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patches: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: May occur; cross tolerance to other nitro compounds have been reported. Appropriate dosing is needed to minimize tolerance development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535366\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299768\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4039431\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12646&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Nitroglycerin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alteplase: Nitroglycerin may decrease the serum concentration of Alteplase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.<b> Exceptions: </b>Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Nitroglycerin may diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202072\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (product specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11313090\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with all products; adverse events were not observed in animal reproduction studies conducted using the ointment. Nitroglycerin crosses the placenta (David 2000). Concentrations following application of a transdermal patch 0.4 mg/hour were low but detectable in the fetal serum (fetal/maternal ratio: 0.23) (Bustard 2003). Nitroglycerin may be used in pregnancy when immediate relaxation of the uterus is needed (ACOG 183 2017; Axemo 1998; Chandraharan 2005). Intravenous nitroglycerin may be used to treat pre-eclampsia with pulmonary edema (ESG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054420\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate (continuously with IV use)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202064\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitroglycerin forms free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3&rsquo;5&rsquo; monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions. For use in rectal fissures, intra-anal administration results in decreased sphincter tone and intra-anal pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202081\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Sublingual tablet: 1 to 3 minutes; Translingual spray: Similar to sublingual tablet; Extended release: ~60 minutes; Topical: 15 to 30 minutes; Transdermal: ~30 minutes; IV: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Sublingual powder: 7 minutes; Sublingual tablet: 5 minutes; Translingual spray: 4 to 15 minutes; Extended release: 2.5 to 4 hours; Topical: ~60 minutes; Transdermal: 120 minutes; IV: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Sublingual tablet: At least 25 minutes; Translingual spray: Similar to sublingual tablet; Extended release: 4 to 8 hours (Gibbons 2002); Topical: 7 hours; Transdermal: 10 to 12 hours; IV: 3 to 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive first-pass effect; metabolized hepatically to glycerol di- and mononitrate metabolites via liver reductase enzyme; subsequent metabolism to glycerol and organic nitrate; nonhepatic metabolism via red blood cells and vascular walls also occurs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~1 to 4 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202085\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (NitroMist Translingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg/spray (4.1 g): $227.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Nitro-Time Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $54.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.5 mg (60): $60.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (60): $70.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Nitroglycerin ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $53.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.5 mg (60): $60.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (60): $66.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Nitro-Bid Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (30 g): $38.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Rectiv Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4% (30 g): $732.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (GoNitro Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (1): $8.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Minitran Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/hour (30): $597.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/hour (30): $616.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/hour (30): $680.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/hour (30): $737.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Nitro-Dur Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/hour (30): $165.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/hour (30): $178.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/hour (30): $200.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/hour (30): $200.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/hour (30): $217.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg/hour (30): $217.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Nitroglycerin Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/hour (30): $55.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/hour (30): $50.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/hour (30): $56.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg/hour (30): $61.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroglycerin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL 5% (250 mL): $21.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/mL 5% (250 mL): $23.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroglycerin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (10 mL): $16.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroglycerin Translingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/spray (4.9 g): $224.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitrolingual Translingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/spray (4.9 g): $330.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Nitroglycerin Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $47.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (25): $25.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $47.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Nitrostat Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $68.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (25): $37.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $68.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202086\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Angiderm Patch (KR);</li>\n      <li>Anginine (AU);</li>\n      <li>Angised (HR, KW, QA, SG);</li>\n      <li>Cardiplast (ES);</li>\n      <li>Cardispray (AE);</li>\n      <li>Cardnit (PK);</li>\n      <li>Deponit (CN, DE, HU, LU, MY, PE, PH);</li>\n      <li>Deponit NT (IL);</li>\n      <li>Dermatrans (ES);</li>\n      <li>Diafusor (LU);</li>\n      <li>Domitral (VN);</li>\n      <li>Enetege (UY);</li>\n      <li>Epinitril (FR);</li>\n      <li>Glytrin (IE, TR);</li>\n      <li>Glytrin Spray (NZ, SG);</li>\n      <li>Herzer (JP);</li>\n      <li>Lycinate (AU);</li>\n      <li>Millisrol (JP);</li>\n      <li>Minitran (AU, BE, CR, DO, GR, GT, HN, LU, MT, PA, SV, UY);</li>\n      <li>Myovin (IN);</li>\n      <li>Natispray (LU);</li>\n      <li>Niglinar (PE);</li>\n      <li>Nit-Ret (CZ);</li>\n      <li>Nitracor (PL);</li>\n      <li>Nitradisc (LU, MX, PT);</li>\n      <li>Nitradisc TTS (GR);</li>\n      <li>Nitral (ID);</li>\n      <li>Nitriderm TTS (FR);</li>\n      <li>Nitril (LK);</li>\n      <li>Nitro (FI, HU);</li>\n      <li>Nitro Mack (LU);</li>\n      <li>Nitro Mack Retard (AE, AT, BH, CY, CZ, EG, GR, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitro Pohl (HU);</li>\n      <li>Nitro-Dur (AE, AU, BB, CH, ES, HU, IT, NO, PL, PT, QA, SA);</li>\n      <li>Nitro-Dur 10 (IL);</li>\n      <li>Nitro-Mack (PL);</li>\n      <li>Nitro-Pflaster (DE);</li>\n      <li>Nitro-Pflaster-ratiopharm (LU);</li>\n      <li>Nitrobaat (BE, NL);</li>\n      <li>Nitrocard (PL);</li>\n      <li>Nitrocerin (GR);</li>\n      <li>Nitrocine (CN, EE, ID, IE);</li>\n      <li>Nitrocine 5 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitrocontin (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LK, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Nitrocontin Continus (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitrocor (IT);</li>\n      <li>Nitroderm (VE);</li>\n      <li>Nitroderm TTS (AE, AR, AT, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CY, DE, EC, EG, ES, ET, GH, GM, GN, GY, HR, HU, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NZ, OM, PL, PT, QA, RO, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Nitroderm TTS Ext (CZ);</li>\n      <li>Nitroderm TTS-5 (NI);</li>\n      <li>Nitrodisc (BM, BS, BZ, GY, JM, MY, SR, TT);</li>\n      <li>Nitrodom (AR);</li>\n      <li>Nitrodyl (GR, LU);</li>\n      <li>Nitrodyl TTS (GR);</li>\n      <li>Nitrogesic (UY);</li>\n      <li>Nitroglycerinum (PL);</li>\n      <li>Nitroglycerinum prolongatum (PL);</li>\n      <li>Nitrol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nitrolingual (AE, AT, BE, CH, DE, DK, GB, GR, HK, HU, IE, KR, LT, LU, MT, NL, PH, PT, SE, SI, TW);</li>\n      <li>Nitrolingual Pumpspray (AU);</li>\n      <li>Nitrolingual Spray (KR, NZ, PH);</li>\n      <li>Nitromack Retard (PY);</li>\n      <li>Nitromaks (UA);</li>\n      <li>Nitromex (NO, SE);</li>\n      <li>Nitromint (HU, PL, RO, SK, TH, UA, VN);</li>\n      <li>Nitromint Aerosol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Nitromint Khi dung (VN);</li>\n      <li>Nitromint Retard (AE, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);</li>\n      <li>Nitronal (FR, RO);</li>\n      <li>Nitronal Aqueous (PH);</li>\n      <li>Nitronal Spray (FR);</li>\n      <li>Nitrong (BE, LU, MT, TR);</li>\n      <li>Nitrong Retard (AT, GR);</li>\n      <li>Nitroplast (ES);</li>\n      <li>Nitroplus (LK);</li>\n      <li>Nitrosol Spray (MY);</li>\n      <li>Nitrospray (UA);</li>\n      <li>Nitrostad Retard (VN);</li>\n      <li>Nitrostat (TW);</li>\n      <li>Nitrovas (BD);</li>\n      <li>Nitrozell Retard (AT, NL);</li>\n      <li>NTG (ID);</li>\n      <li>Nysconitrine (LU);</li>\n      <li>Nyserin (PH);</li>\n      <li>Perlinganit (BG, HU, KR, LU, PL);</li>\n      <li>Ratiopharm (DE);</li>\n      <li>Rectogesic (AU, BE, CH, CZ, DE, DK, FI, FR, GB, IE, IL, IT, NL, NO, NZ, PT, SE, SG, SK, TR);</li>\n      <li>Rectogesic Ointment (KR);</li>\n      <li>Sustac (AE, BH, BM, BS, BZ, CY, EG, GY, HR, HU, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);</li>\n      <li>Sustonit (PL);</li>\n      <li>Transiderm Nitro (AU, FI, IE, NL, NO, SE);</li>\n      <li>Tridil (BR);</li>\n      <li>Trimonit (PL);</li>\n      <li>Trinipatch (LU);</li>\n      <li>Venitrin (IT);</li>\n      <li>Willlong (LU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: Postpartum Hemorrhage,&quot; <i>Obstet Gynecol</i>, 2006, 108(4):1039-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/17012482/pubmed\" target=\"_blank\" id=\"17012482\">17012482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children.<i> Am Heart J</i>. 1987;113(4):994-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/3031972 /pubmed\" target=\"_blank\" id=\"3031972 \">3031972 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Axemo P, Fu X, Lindberg B, et al, &quot;Intravenous Nitroglycerin for Rapid Uterine Relaxation,&quot; <i>Acta Obstet Gynecol Scand</i>, 1998, 77(1):50-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9492718/pubmed\" target=\"_blank\" id=\"9492718\">9492718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    B&ouml;ttiger Y, &quot;Lack of Data on Glyceryl Trinitrate Risks in Breast Feeding,&quot; <i>Lakartidningen</i>, 2010, 107(22):1483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/20645601/pubmed\" target=\"_blank\" id=\"20645601\">20645601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bustard MA, Ryan G, Seaward G, et al, &quot;Human Maternal and Fetal Plasma Glyceryl Trinitrate Concentrations,&quot; <i>Am J Obstet Gynecol</i>, 2003, 189(6):1777-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/14710114/pubmed\" target=\"_blank\" id=\"14710114\">14710114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chameides L, Samson RA, Schexnayder SM, et al., eds. <i>Pediatric Advanced Life Support Provider Manual</i>. American Heart Association; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandraharan E and Arulkumaran S, &quot;Acute Tocolysis,&quot; <i>Curr Opin Obstet Gynecol</i>, 2005, 17(2):151-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/15758607/pubmed\" target=\"_blank\" id=\"15758607\">15758607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    David M, Walka MM, Schmid B, et al, &quot;Nitroglycerin Application During Cesarean Delivery: Plasma Levels, Fetal/Maternal Ratio of Nitroglycerin, and Effects in Newborns,&quot;<i> Am J Obstet Gynecol</i>, 2000, 182(4):955-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/10764480/pubmed\" target=\"_blank\" id=\"10764480\">10764480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. <i>Plast Reconstr Surg</i>. 1989;84(5):811-813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/2510208 /pubmed\" target=\"_blank\" id=\"2510208 \">2510208 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elkayam U, &ldquo;Tolerance to Organic Nitrates: Evidence, Mechanisms, Clinical Relevance, and Strategies for Prevention,&rdquo; <i>Ann Intern Med</i>, 1991, 114(8):667-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/2003715 /pubmed\" target=\"_blank\" id=\"2003715 \">2003715 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al, &quot;ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy: The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC),&quot; <i>Eur Heart J</i>, 2011, 32(24):3147-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman WF and George BL, &quot;Treatment of Congestive Heart Failure by Altering Loading Conditions of the Heart,&quot; <i>J Pediatr</i>, 1985, 106(5):697-706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/3923176/pubmed\" target=\"_blank\" id=\"3923176\">3923176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr., Fihn SD, Fraker TD Jr., Gardin JM, O&rsquo;Rourke RA, Pasternak RC, Williams SV. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GoNitro (nitroglycerin) [prescribing information]. Jacksonville, FL: Espero Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilbawi MN, Idriss FS, DeLeon SY, Berry TE, Duffy CE, Paul MH. Hemodynamic effects of intravenous nitroglycerin in pediatric patients after heart surgery. <i>Circulation</i>. 1985;72(3 Pt 2):II101-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/3928187 /pubmed\" target=\"_blank\" id=\"3928187 \">3928187 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laitinen P, Happonen JM, Sairanen H, et al, &quot;Amrinone Versus Dopamine-Nitroglycerin After Reconstructive Surgery for Complete Atrioventricular Septal Defect,&quot; <i>J Cardiothorac Vasc Anesth</i>, 1997, 11(7):870-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9412887/pubmed\" target=\"_blank\" id=\"9412887\">9412887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laitinen P, Happonen JM, Sairanen H, et al, &quot;Amrinone Versus Dopamine and Nitroglycerin in Neonates After Arterial Switch Operation for Transposition of the Great Arteries,&quot; <i>J Cardiothorac Vasc Anesth</i>, 1999, 13(2):186-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/10230954/pubmed\" target=\"_blank\" id=\"10230954\">10230954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee HA and Anderson PO, &ldquo;Giving Partial Doses of Transdermal Patches,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(15):1759-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/9262751/pubmed\" target=\"_blank\" id=\"9262751\">9262751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minitran (nitroglycerin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitro-Bid (nitroglycerin) [prescribing information]. Melville, NY: Savage Pharmaceuticals; September 2011</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitro-Dur (nitroglycerin) [prescribing information]. Whitehouse Station, NJ: Merck; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitroglycerin in 5% Dextrose Injection (nitroglycerin) [package insert]. Deerfield, IL: Baxter; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitrolingual (nitroglycerin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NistroMist (nitroglycerin) [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals, LLC; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitrostat (nitroglycerin) [prescribing information]. Morris Plains, NJ: Parke-Davis; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Connor RE, Brady W, Brooks SC, et al, &quot;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Care Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/20956226/pubmed\" target=\"_blank\" id=\"20956226\">20956226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al, &quot;2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2013, 127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/23256914/pubmed\" target=\"_blank\" id=\"23256914\">23256914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Sullivan S and Keith MP, &quot;Raynaud phenomenon of the Nipple: A Rare Finding in Rheumatology Clinic,&quot; <i>J Clin Rheumatol</i>, 2011, 17(7):371-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/21946463/pubmed\" target=\"_blank\" id=\"21946463\">21946463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. <i>Neurol Clin</i>. 2008;26(2):521-541.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/18514825/pubmed\" target=\"_blank\" id=\"18514825\">18514825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rectiv (nitroglycerin) [prescribing information]. Birmingham, AL: Aptalis Pharma US, Inc; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restieaux M, Maw A, Broadbent R, Jackson P, Barker D, Wheeler B. Neonatal extravasation injury: prevention and management in Australia and New Zealand - a survey of current practice. <i>BMC Pediatr</i>. 2013;13:34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/23497004 /pubmed\" target=\"_blank\" id=\"23497004 \">23497004 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/24420913 /pubmed\" target=\"_blank\" id=\"24420913 \">24420913 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sawatzky-Dickson D, Bodnaryk K. Neonatal intravenous extravasation injuries: evaluation of a wound care protocol. <i>Neonatal Netw</i>. 2006;25(1):13-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/16514862 /pubmed\" target=\"_blank\" id=\"16514862 \">16514862 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thigpen JL. Peripheral intravenous extravasation: nursing procedure for initial treatment. <i>Neonatal Netw</i>. 2007;26(6):379-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/18069429 /pubmed\" target=\"_blank\" id=\"18069429 \">18069429 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treadwell T. The management of intravenous infiltration injuries in infants and children. <i>Ostomy Wound Manage</i>. 2012;58(7):40-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/22798353 /pubmed\" target=\"_blank\" id=\"22798353 \">22798353 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams RS, Mickell JJ, Young ES, et al, &quot;Methemoglobin Levels During Prolonged Combined Nitroglycerin and Sodium Nitroprusside Infusions in Infants After Cardiac Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 1994, 8(6):658-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/7880995/pubmed\" target=\"_blank\" id=\"7880995\">7880995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong AF, McCulloch LM, Sola A. Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates. <i>J Pediatr</i>. 1992;121(6):980-983.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/1447671 /pubmed\" target=\"_blank\" id=\"1447671 \">1447671 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroglycerin-glyceryl-trinitrate-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12646 Version 204.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202098\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202099\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054421\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675227\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054413\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202076\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F202061\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50063776\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054425\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472968\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F202093\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054424\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202157\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4040395\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202065\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535366\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299768\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4039431\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202072\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11313090\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054420\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202064\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F202081\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F202085\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202086\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12646|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">Nitroglycerin (glyceryl trinitrate): Drug information</a></li><li><a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-patient-drug-information\" class=\"drug drug_patient\">Nitroglycerin (glyceryl trinitrate): Patient drug information</a></li></ul></div></div>","javascript":null}